IDSA 2025 复杂尿路感染指南:静脉转口服抗生素的时机
美国感染病学会(IDSA)2025 年复杂尿路感染(cUTI)指南聚焦静脉转口服抗生素的时机。专家组基于 2000 年以来系统文献综述的证据,按 GRADE 方法评级,建议临床改善、能口服药物且有有效口服选项的 cUTI 患者转为口服治疗,无论是否合并革兰阴性菌血症。
要点
- 临床改善、可口服给药且有有效口服药时,cUTI 应转口服而非继续静脉治疗。
- 合并革兰阴性菌血症不影响转口服的推荐。
- 有效口服药需对致病菌有活性,并在尿液和相关组织达到治疗浓度。
核心结论
- 对临床改善、能口服药物且有有效口服选项的 cUTI 患者,建议转口服抗生素完成疗程,而非继续胃肠外治疗,无论是否合并革兰阴性菌血症。
- 用于完成 cUTI 疗程的胃肠外与口服抗生素疗效和不良事件相似,尤其是在较短疗程背景下。
研究设计与样本
- IDSA 制定的临床实践指南,证据来自聚焦于转口服治疗与全程胃肠外治疗利弊比较的系统文献综述,纳入 2000 年以来的发表文献。
- 推荐采用 GRADE 方法对证据确定性及推荐强度进行标准化评级。
主要发现
- 专家组建议在临床改善、能口服药物且有有效口服选项的 cUTI 患者中转口服抗生素,而非继续胃肠外治疗至疗程结束。
- 该建议不因是否合并革兰阴性菌血症而改变。
- 有效口服选项需对致病病原体有活性,并在尿液及相关组织中达到治疗浓度。
- 胃肠外与口服抗生素用于完成 cUTI 疗程时疗效与不良事件相似,尤其在短疗程背景下。
关键数值与推荐
- 转口服条件:临床改善、能口服药物、有有效口服选项。
- 有效口服选项需覆盖致病菌并在尿液与相关组织达到治疗浓度。
- 合并革兰阴性菌血症不构成继续胃肠外治疗的理由。
临床怎么用
- 对符合临床改善、可口服给药且有有效口服药的 cUTI 患者及时转口服,以减少静脉导管相关不良事件、费用与资源消耗。
- 选择口服药时确认其对致病菌的活性及在尿液和相关组织的治疗浓度。
- 制定方案时兼顾抗菌药物给药的实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: These recommendations provide guidance on the optimal timing for transitioning from intravenous to oral antibiotics in patients with complicated urinary tract infection (cUTI), especially in presence of associated Gram-negative bacteremia. METHODS: The panel's recommendations are based upon evidence derived from systematic literature reviews which focused on comparative benefits and harms of transitioning to oral therapy versus continuing parenteral therapy of the total duration of treatment, including publications since 2000. These recommendations adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. RESULTS: The guidelines panel suggests transitioning to oral antibiotics in patients with cUTI who are clinically improving, able to take medication, and for whom an effective oral option is available, rather than continuing parenteral therapy for the remaining treatment duration, regardless of the presence of associated Gram-negative bacteremia. An effective oral option needs to be active against the causative pathogen and achieve therapeutic levels in the urine and relevant tissue. CONCLUSIONS: Parenteral and oral antibiotics used to complete treatment courses for cUTI provide similar efficacy and adverse events, especially in the context of shorter duration of therapy. This recommendation places a high value on reducing avoidable intravenous catheter-related adverse events, costs, and resources, as well as taking into account practical aspects of antibiotic administration.
引用
- Trautner BW, Cortés-Penfield NW, Gupta K, et al. Clinical Practice Guidelines by Infectious Diseases Society of America: 2025 Guidelines on Management and Treatment of Complicated Urinary Tract Infections - Timing of Intravenous to Oral Antibiotics Transition for Complicated Urinary Tract Infections. Clin Infect Dis. 2026. PMID: 41414903. doi:10.1093/cid/ciaf461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。